# A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

> **NCT02597049** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 424 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** Placebo
- **DRUG:** SGLT2 inhibitor
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02597049
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 424 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597049, "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02597049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*